Table 1—

Characteristics of the study cohort of 289 patients with severe community-acquired pneumonia

Age yrs69.7±13.8
Females99 (34.3)
PSI score112.9±25.7
 Class IV198 (68.5)
 Class V52 (18.0)
APACHE II score13.8±4.6
Comorbidity180 (62.3)
 Congestive heart failure36 (12.5)
 Neoplasm65 (22.5)
 Liver disease3.0 (1.0)
 Cerebrovascular disease25 (8.7)
 Chronic renal disease27 (9.3)
 COPD88 (30.4)
Clinical features
 Temperature °C38.5±1.2
 Respiratory rate breaths·min−126.7±8.7
Laboratory data
 CRP mg·L−1174 (147–390)
 White blood cell count 109·L−116.5±9.2
Antibiotic therapy
 β-lactam232 (80.3)
  Amoxicillin ± clavulanic acid169 (58.5)
  Cephalosporin (2nd or 3rd generation)60 (20.7)
   Cephtriaxone47 (16.2)
   Cephtazidime12 (4.2)
   Cephotaxime1 (0.3)
  Penicillin3 (1.0)
 β-lactam/macrolide combination47 (16.3)
  Amoxicillin ± clavulanic acid and macrolide32 (11.1)
  Cephalosporin (2nd or 3rd generation) and macrolide14 (4.8)
   Cephtriaxone and macrolide11 (3.8)
   Cephtazidime and macrolide2 (0.7)
 Other#10 (3.5)
Outcome
 ICU admissions during hospitalisation9 (3.1)
 28-day mortality20 (6.9)
  • Data are presented as mean±sd, n (%) or median (interquartile range). PSI: Pneunomia Severity Index; APACHE: Acute Physiology and Chronic Health Evaluation; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ICU: intensive care unit. #: other antibiotics include: cotrimoxazole (n = 2; 0.7%); β-lactam and ciprofloxacin (n = 2; 0.7%); doxycyclin (n = 2; 0.7%); erytromycin and rifampicin (n = 1; 0.3%); levofloxacin (n = 1; 0.3%); and erythromycin (n = 2; 0.6%).